Gyre Therapeutics Files 8-K on Financial Condition & Regulation FD

TL;DR

**GYRE THERAPEUTICS just filed an 8-K indicating a financial update, likely an earnings release, on February 8, 2024.**

AI Summary

Gyre Therapeutics, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 8, 2024. The filing indicates disclosure related to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure,' suggesting a financial update or earnings release. The document also includes 'Financial Statements and Exhibits,' though specific financial figures are not detailed in this excerpt.

Why It Matters

This 8-K signals that Gyre Therapeutics is providing an update on its financial performance, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — The filing itself is a procedural disclosure of an event, not the event's content, so it carries low inherent risk without specific financial details.

Key Players & Entities

• GYRE THERAPEUTICS, INC. (company) — Registrant
• CATALYST BIOSCIENCES, INC. (company) — Former company name
• TARGACEPT INC (company) — Former company name
• February 8, 2024 (date) — Date of earliest event reported
• February 14, 2024 (date) — Filing date
• 000-51173 (other) — Commission File Number
• 56-2020050 (other) — IRS Employer Identification No.
• 12770 High Bluff Drive, Suite 150, San Diego, CA 92130 (other) — Business address
• (619) 949-3681 (other) — Business phone number

FAQ

Key Financial Figures

• $385,000 — by agreeing to pay an aggregate fee of $385,000 to counsel for Bushansky and Scott in f

Filing Documents

• ef20021723_8k.htm (8-K) — 43KB
• ef20021723_ex99-1.htm (EX-99.1) — 787KB
• image00001.jpg (GRAPHIC) — 1KB
• 0001140361-24-008051.txt ( ) — 1019KB
• gyre-20240208.xsd (EX-101.SCH) — 4KB
• gyre-20240208_lab.xml (EX-101.LAB) — 22KB
• gyre-20240208_pre.xml (EX-101.PRE) — 16KB
• ef20021723_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. The information set forth below under "Preliminary Financial Information for the Year Ended December 31, 2023" in Item 7.01 is incorporated by reference herein.

01

Item 7.01. Regulation FD Disclosure. Preliminary Financial Information for the Year Ended December 31, 2023 On February 14, 2024, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (" GNI Group "), which holds an indirect controlling interest of Gyre Therapeutics, Inc., a Delaware corporation (the " Company "), issued a press release reporting financial results for the quarter and year ended December 31, 2023. GNI Group also disclosed information regarding GNI Group's and the Company's financial position and near-term catalysts, including the Company's expected Investigational New Drug application submission for Hydronidone by end of year 2024 and Beijing Continent Pharmaceuticals Co., Ltd.'s expected last patient observation in 2024 for its Phase 3 clinical trial of Hydronidone in China. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

Forward Looking Statements

Forward Looking Statements This report and the press release attached as an exhibit contain forward-looking statements that pertain to future operating performance and that are not historic facts. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group and/or the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements. Notice of Dismissal of Catalyst Biosciences, Inc. Litigation and Agreement Upon Attorneys' Fees On December 26, 2022, Catalyst Biosciences, Inc. (" Catalyst "), now known as Gyre Therapeutics, Inc. (the " Company "), entered into a Business Combination Agreement , as amended on March 29, 2023 and August 30, 2023 (the " Business Combination Agreement "), by and among Catalyst, GNI USA, Inc., a Delaware corporation (" GNI USA "), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (" GNI Group "), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (" GNI HK "), Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China (" Shanghai Genomics "), the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (" CPI ") (such transactions contemplated by the Business Combination Agreement, collectively, the " Contributions "). Pursuant to the terms of the Business Comb

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated February 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: February 14, 2024 By: /s/ Han Ying, Ph.D. Name: Han Ying, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR